# Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

> **NCT07037004** · PHASE2 · NOT_YET_RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 62 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Stage II Renal Cell Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Clostridium butyricum CBM588 Strain
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07037004
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-04
- **Primary completion:** 2028-10-24
- **Final completion:** 2028-10-24
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07037004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07037004, "Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07037004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*